[Sulfinpyrazone-associated renal failure (author's transl)].
Three patients developed renal failure a few days after onset of sulfinpyrazone administration. In two the renal dysfunction was reversible, while the third died of a second myocardial infarction. The clinical picture of renal failure was uncharacteristic. It is recommended that renal function be tested two to four days after starting sulfinpyrazone, and to discontinue the drug immediately if there is a rise in blood urea nitrogen and creatinine. Since in two of the patients the creatinine values were elevated before sulfinpyrazone had been administered, it is clear that even minor pointers to impaired renal function should be considered as contraindications to the use of sulfinpyrazone.
D058186:Acute Kidney Injury / Q000139:chemically induced*; D000328:Adult; D000368:Aged; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D013442:Sulfinpyrazone / Q000009:adverse effects* / Q000627:therapeutic use
D008801:Mexiletine; D003404:Creatinine; D013442:Sulfinpyrazone; D007213:Indomethacin
Sulfinpyrazon-assoziierte Niereninsuffizienz.